A Phase 3 interventional study of Cipaglucosidase Alfa and Miglustat in Pompe Disease (Late-onset), sponsored by Amicus Therapeutics. Active, not recruiting at 17 sites in 6 countries. Open to participants aged 0 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Glycogen Storage Disease Type II by BioMarin Pharmaceutical — 2 open to participants now, 3 under way, 2 of them phase 3. Glycogen Storage Disease Type II · BioMarin Pharmaceutical.
Among the 16 studies in Glycogen Storage Disease Type II by BioMarin Pharmaceutical, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2020, is one of 5 in phase 3, and was the 12th registered.
162 studies on the registry are indexed under Glycogen Storage Disease Type II; 34 are open to participants now.
Browse Glycogen Storage Disease Type II studies →2 of the 16 studies in Glycogen Storage Disease Type II by BioMarin Pharmaceutical are open now, in 12 countries. Recruiting first, the newest first:
Amicus Therapeutics · Sites in United States, Austria, Belgium and 9 more countries
Amicus Therapeutics · Sites in United States, Germany, Italy and 3 more countries
Ages up to 17
By country, each count listing its studies:
Of the 23 Glycogen Storage Disease Type II studies recruiting now, 16 (70%) set no upper age limit and 6 (26%) stop at 75 or younger; 15 take children under 18; none take healthy volunteers.
This study: 0 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 5
First in 2007; this study’s year is marked. 1 started in 2020.
This study's enrollment of 21 is close to the median of 20 across 89 interventional studies indexed under Glycogen Storage Disease Type II.
Median enrollment 25 across the 10 interventional studies, 21 across the 4 observational. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Amicus Therapeutics, one of the names counted as BioMarin Pharmaceutical. Under that name alone:
Amicus Therapeutics is the lead sponsor of 42 studies on the registry; 8 are open to participants now.
2 of the studies in Glycogen Storage Disease Type II by BioMarin Pharmaceutical that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03911505Phase 3Amicus TherapeuticsZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD | 2027-03 |
| NCT04808505Phase 3Amicus TherapeuticsA Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18 | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Glycogen Storage Disease Type II by BioMarin Pharmaceutical, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD, and immunogenicity of Cipaglucosidase Alfa/Miglustat treatment in enzyme replacement therapy (ERT)-experienced and ERT-naïve pediatric subjects with Pompe disease, aged 0 to \< 18 years
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Cipaglucosidase Alfa (ATB200) co-administered with Miglustat (AT2221) capsule
Biological: Cipaglucosidase Alfa · Drug: Miglustat
Enzyme Replacement Therapy via intravenous infusion
Also known as: ATB200
Participants received Cipaglucosidase Alfa (ATB200) co-administered with Miglustat(AT2221)
Also known as: AT2221
Incidence of treatment-emergent adverse events (TEAEs) from baseline
Time frame: 52 weeks
Assessment of pharmacokinetic parameters
ATB200 and AT2221 concentrations in plasma
Time frame: 52 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2020 (actual). Primary completion is estimated for Mar 2027, 85 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cipaglucosidase alfa
Glycogen Storage Disease Type II →